Literature DB >> 17286243

[Polyposis nasi--improvement in quality of life by the influence of leukotrien receptor antagonists].

C Pauli1, R Fintelmann, C Klemens, E Hilgert, F Jund, G Rasp, H Hagedorn, M F Kramer.   

Abstract

BACKGROUND: Sulfido-Leukotrienes are important inflammatory mediators of bronchial asthma, intolerance of acetylsalicylic acid (ASA), polyposis nasi and allergic rhinitis. Receptorantagonists like Montelukast constitute a well-established asthma- and ASA intolerance-therapy. The aim of our study was to evaluate changes in patients Health-Related-Quality-of-Life (HRQL) during Montelukast-monotherapy of nasal polyposis.
METHODS: The study was performed in a prospective, double blind and placebo-controlled matter. The study included 30 patients of our ENT outpatient's dept. (77 % male, mean age 49 yrs), suffering from nasal polyposis grade II to IV. Polyps were endoscopically graded, nasal Eosinophilic Cationic Protein (ECP) was measured, and HRQL-score was taken prior to and four weeks after Montelukast-(0 - 0 - 10 mg) compared to placebo. An established HRQL-questionnaire - including 25 items, summarized in 6 symptom-groups - was used. Given was a symptom-score of 1 (not troubled) to 4 (extremely troubled).
RESULTS: Patients treated with Montelukast improved their nasal symptoms (Delta HRQL-score 0.58 +/- 0.94, P < 0.01), practical problems (Delta HRQL-score 0.42 +/- 0.71, P < 0.05), headaches (Delta HRQL-score 0.38 +/- 0.56, P < 0.05), non-nasal symptoms (Delta HRQL-score 0.35 +/- 0.92, P < 0.05), sleep (Delta HRQL-score 0.26 +/- 0.71) and emotional problems (Delta HRQL-score 0.18 +/- 0.75). Intranasal ECP (Delta 210.67 ng/ml +/- 332.68) and polyp grading (Delta 0.72 +/- 1.77) tended to improve as well, but did not reach statistical significance. Patients treated with placebo revealed no significant changes neither in HRQL-score, ECP, nor polyp grading.
CONCLUSIONS: Montelukast-therapy of nasal polyposis significantly improved patient's HRQL in 4 out of 6 symptom-groups. Measuring HRQL proofed to constitute a more sensitive tool than looking at eosinophilic parameters of inflammation or polyp size.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17286243     DOI: 10.1055/s-2007-966094

Source DB:  PubMed          Journal:  Laryngorhinootologie        ISSN: 0935-8943            Impact factor:   1.057


  9 in total

Review 1.  Role of medical therapy in the management of nasal polyps.

Authors:  Isam Alobid; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

Review 2.  Leukotriene antagonists in nasal polyposis: a meta-analysis and systematic review.

Authors:  Jennifer L Wentzel; Zachary M Soler; Kristen DeYoung; Shaun A Nguyen; Shivangi Lohia; Rodney J Schlosser
Journal:  Am J Rhinol Allergy       Date:  2013 Nov-Dec       Impact factor: 2.467

3.  [ASA-intolerance syndrome and persistent rhinosinusitis : Differential diagnosis and treatment].

Authors:  H Kirsche; L Klimek
Journal:  HNO       Date:  2015-05       Impact factor: 1.284

Review 4.  Evidence and evidence gaps in therapies of nasal obstruction and rhinosinusitis.

Authors:  Nicole Rotter
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2016-12-15

Review 5.  Chinese Society of Allergy and Chinese Society of Otorhinolaryngology-Head and Neck Surgery Guideline for Chronic Rhinosinusitis.

Authors:  Zheng Liu; Jianjun Chen; Lei Cheng; Huabin Li; Shixi Liu; Hongfei Lou; Jianbo Shi; Ying Sun; Dehui Wang; Chengshuo Wang; Xiangdong Wang; Yongxiang Wei; Weiping Wen; Pingchang Yang; Qintai Yang; Gehua Zhang; Yuan Zhang; Changqing Zhao; Dongdong Zhu; Li Zhu; Fenghong Chen; Yi Dong; Qingling Fu; Jingyun Li; Yanqing Li; Chengyao Liu; Feng Liu; Meiping Lu; Yifan Meng; Jichao Sha; Wenyu She; Lili Shi; Kuiji Wang; Jinmei Xue; Luoying Yang; Min Yin; Lichuan Zhang; Ming Zheng; Bing Zhou; Luo Zhang
Journal:  Allergy Asthma Immunol Res       Date:  2020-03       Impact factor: 5.764

6.  Aspirin sensitivity and chronic rhinosinusitis with polyps: a fatal combination.

Authors:  Hendrik Graefe; Christina Roebke; Dirk Schäfer; Jens Eduard Meyer
Journal:  J Allergy (Cairo)       Date:  2012-08-14

7.  Chronic rhinosinusitis and emerging treatment options.

Authors:  Patorn Piromchai; Pornthep Kasemsiri; Supawan Laohasiriwong; Sanguansak Thanaviratananich
Journal:  Int J Gen Med       Date:  2013-06-07

8.  Health-Related Quality of Life Assessed in Children with Chronic Rhinitis and Sinusitis.

Authors:  Lechosław Paweł Chmielik; Grażyna Mielnik-Niedzielska; Anna Kasprzyk; Tomasz Stankiewicz; Artur Niedzielski
Journal:  Children (Basel)       Date:  2021-12-04

Review 9.  Position statement of the Brazilian Academy of Rhinology on the use of antihistamines, antileukotrienes, and oral corticosteroids in the treatment of inflammatory sinonasal diseases.

Authors:  Olavo de Godoy Mion; João Ferreira de Mello; Daniel Lorena Dutra; Nilvano Alves de Andrade; Washington Luiz de Cerqueira Almeida; Wilma Teresinha Anselmo-Lima; Leonardo Lopes Balsalobre Filho; Jair de Carvalho E Castro; Roberto Eustáquio Dos Santos Guimarães; Marcus Miranda Lessa; Sérgio Fabrício Maniglia; Roberto Campos Meireles; Márcio Nakanishi; Shirley Shizue Nagata Pignatari; Renato Roithmann; Fabrizio Ricci Romano; Rodrigo de Paula Santos; Marco César Jorge Dos Santos; Edwin Tamashiro
Journal:  Braz J Otorhinolaryngol       Date:  2017-01-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.